"I find it interesting that AMRN cannot explain how their drug causes reduced CV risk...there are only hypotheses. RVX has worked very hard in the last few years to study how Apabetalone downregulates different elements that raise CV risk."

I think Resverlogix will be in a similar position with apabetalone, as Amarin is in with Vascepa and omega-3s. Lots of potential pathways modulated by apabetalone and Vascepa, but uncertain which one(s) are responsible for any MACE reduction.